JAK Inhibitors and Emerging Therapies in Psoriatic Arthritis

This chapter delves into clinical findings related to JAK inhibitors, particularly focusing on the IL-23 inhibitor gazelcomab and its comparable efficacy across genders. It further discusses biomarker insights, treatment outcomes, and safety profiles of bimikizumab, emphasizing its effectiveness in improving pain and fatigue in patients with psoriatic arthritis.